Inventor · disambiguated record
Jee H. Kim
Also filed as: KIM JEE · KIM JEE H · KIM JEE HAE
16 granted patents·5 pending applications·56 citations·filing 1999–2025
91Inventor score
Top patents by PatentIndex Score
21 records- 0193US9644018B2Antibody modulators of APLNRREGENERON PHARMA·Filed 2015·Granted May 9, 2017·13 cites·11 claims
- 0292US11884736B2Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)REGENERON PHARMA·Filed 2021·Granted Jan 30, 2024·2 cites·12 claims
- 0388US9120851B2Human antibodies to human angiopoietin-like protein 4REGENERON PHARMA·Filed 2012·Granted Sep 1, 2015·11 cites·11 claims
- 0487US10626173B2Method for treating pathological angiogenesis by administering an antibody that inhibits APLNRREGENERON PHARMA·Filed 2018·Granted Apr 21, 2020·2 cites·20 claims
- 0583US2024091301A1APLNR Modulators and Uses ThereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0682US10947310B2Fusion protein comprising apelin and an anti-APLNR antibodyREGENERON PHARMA·Filed 2018·Granted Mar 16, 2021·1 cites·20 claims
- 0782US10189901B2Methods for improving cardiac function by administering an antibody that activates APLNRREGENERON PHARMA·Filed 2017·Granted Jan 29, 2019·2 cites·13 claims
- 0881US8354103B2Human antibodies to human angiopoietin-like protein 4REGENERON PHARMA·Filed 2010·Granted Jan 15, 2013·5 cites·6 claims
- 0979US10155811B2APLNR modulators and uses thereofREGENERON PHARMA·Filed 2014·Granted Dec 18, 2018·2 cites·20 claims
- 1076US11578127B2Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereofREGENERON PHARMA·Filed 2019·Granted Feb 14, 2023·1 cites·17 claims
- 1176US10390779B2X-ray imaging apparatus and control method thereofSAMSUNG ELECTRONICS CO LTD·Filed 2017·Granted Aug 27, 2019·4 cites·22 claims
- 1275US12421317B2Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodiesREGENERON PHARMA·Filed 2023·Granted Sep 23, 2025·0 cites·15 claims
- 1375US11642390B2Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibodyREGENERON PHARMA·Filed 2021·Granted May 9, 2023·0 cites·18 claims
- 1473US12441797B2Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereofREGENERON PHARMA·Filed 2023·Granted Oct 14, 2025·0 cites·14 claims
- 1573US2024124554A1Vegf traps and mini-traps and methods for treating ocular disorders and cancerREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1665US12103960B2VEGF traps and mini-traps and methods for treating ocular disorders and cancerREGENERON PHARMA·Filed 2021·Granted Oct 1, 2024·0 cites·10 claims
- 1762US2024425574A1Anti-pdgf-b antibodies and pharmaceutical composition thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1861US6723838B1Signal transducing synaptic molecules and uses thereofUNIV JOHNS HOPKINS·Filed 1999·Granted Apr 20, 2004·13 cites·1 claims
- 1958US12030935B2Anti-PDGF-B antibodies and pharmaceutical composition thereofREGENERON PHARMA·Filed 2022·Granted Jul 9, 2024·0 cites·9 claims
- 2048US2025276092A1Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody responseREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2142US2019002555A1Antigen-binding proteins to marinobufageninREGENERON PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jee H. Kim files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →